Clinical Education InitiativeMenu
Search
Home > Courses > ACTHIV 2016 Conference - Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World

ACTHIV 2016 Conference - Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World

ACTHIV 2016 Conference - Treating Hepatitis C-HIV Coinfected Patients Welcome to the Real World
Play
Sorry, this learning module is not available for mobile devices.
ACTHIV
Original Presentation: 4/29/2016
Web Posting: 9/15/2016

The enduring material is jointly provided by William Beaumont Hospital, American Academy of CME, Inc., and the American Conference for the Treatment of HIV (ACTHIV).

The 10th Annual American Conference for the Treatment of HIV (ACTHIV) was held April 28-30, 2016 in Dallas, TX. The Conference was supported by funding from the Clinical Education Initiative, New York State Department of Health, AIDS Institute; and from the HIV Medicine Association (HIVMA). The conference and this web archive were supported by educational grants from Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics, Division of Janssen Products, LP; Merck & Co.; and ViiV Healthcare.

ONLINE CE CREDIT:

This module is NO LONGER available for CE credit.

FACULTY:
H. Nina Kim, MD, MSc, is an Associate Professor of Medicine and Adjunct Associate Professor of Global Health at the University of Washington (UW). She is the Director of the Madison HIV/Hepatitis Coinfection Clinic at Harborview Medical Center in Seattle.

Estimated time to complete: 30 minutes

TARGET AUDIENCE
Physicians (both specialists and primary care/family medicine), nurse practitioners, and nurses who are frontline providers of care to persons at risk of or with HIV infection. Physician assistants, pharmacists, case managers and other healthcare professionals may also participate.

Learning Objectives
As a result of participating in this activity, participants should be better able to:

  • Select appropriate DAA therapy in HIV-HCV coinfected patients.
  • Discuss some real-world HCV treatment issues related to choice of direct-acting antiviral (DAA) therapy in HIV-HCV coinfected patients
  • Identify relevant drug interactions with DAAs and antiretroviral therapy
  • Recognize some important adverse events of currently available DAAs
  • Highlight the potential for HCV reinfection after treatment clearance

Faculty Disclosure

H. Nina Kim, MD, MSc – no relevant financial relationships to disclose.

Privacy Policy
For more information about Beaumont’s privacy policy, please access http://www.beaumont.edu/privacy-policy
For more information about Academy privacy policy, please access http://www.academycme.org/privacy.htm

For CME information or credit details, contact: cme@beaumont.edu

For CNE information or credit details, contact: CEservices@academycme.org

Bibliographic Sources:

Presenter
  • H. Nina Kim, MD, MSc
    Associate Professor of Science
    University of Washington
Presenter Bio
H. Nina Kim, MD, MSc

Dr. Nina Kim is an Associate Professor of Medicine and Adjunct Associate Professor of Global Health at the University of Washington (UW). She is the Director of the Madison HIV/Hepatitis Coinfection Clinic at Harborview Medical Center in Seattle, WA. She received her medical degree at University of California San Francisco and completed her training in internal medicine and infectious disease at the University of Washington. She serves as the Associate Editor of Hepatitis C Online, a CDC-sponsored web-based curriculum and is the lead investigator for the Liver Disease section of the UW Center for AIDS Research Clinical Epidemiology & Health Services Research Core.